Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data.
Viviana MoscheseClementina CanessaAntonino TrizzinoBaldassarre MartireGiorgio Maria BoggiaSimona Grazianinull nullPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2020)
In pediatric PID patients, weekly and biweekly Hizentra® administrations appeared equally effective treatment options.